Roche
Search results
Actelion is a pharmaceuticals and biotechnology company established in December 1997, headquartered in Allschwil near Basel, Switzerland. Actelion focuses on the manufacture of drugs that treat rare and orphan diseases.
Headquartered in Allschwil, Actelion is part of the Johnson & Johnson Family of Companies. Its ground-breaking research and medicines have been a key contributor to improve the lives of people affected by pulmonary hypertension, and made Actelion an industry leader in this area.
May 5, 2024 · Supported by Actelion’s 20-year heritage of pioneering innovation, we are working to reach more patients and aim to help tackle the diagnosis gap that is delaying access to the care that patients need. We want to use our full range of resources to tackle PH.
Jun 16, 2017 · The acquisition was completed through an all-cash public tender offer by Johnson & Johnson’s Swiss subsidiary, Janssen Holding GmbH, to acquire all publicly held shares of Actelion Ltd for $280 per share, payable in U.S. dollars. Actelion will now become part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Jan 26, 2017 · Actelion has established a leading franchise of differentiated, innovative products for pulmonary arterial hypertension (PAH) that is highly complementary to the existing portfolio of the...
Sep 6, 2017 · TRACLEER is an orally active endothelin receptor antagonist (ERA) for the treatment of patients with PAH (WHO Group 1). This approval covers a new 32 mg dosage of TRACLEER, which features a scored tablet. The tablet can be dispersed in a teaspoon of water before oral administration.
May 16, 2017 · What makes Actelion such a natural fit for a Johnson & Johnson acquisition? A: Actelion brings to Johnson & Johnson a best-in-class, paradigm-shifting portfolio of medicines that can help address an important medical need: pulmonary arterial hypertension.
Jan 26, 2017 · Johnson & Johnson has confirmed it is to acquire Swiss biotech Actelion for £30 billion, after beating off competition from Sanofi to clinch its biggest ever deal.
Actelion (now Janssen Pulmonary Hypertension) | 53,960 followers on LinkedIn. We're now part of Janssen. For future updates, please visit our LinkedIn channel: 'Janssen Pharmaceutical Companies...
Jan 26, 2017 · Johnson & Johnson on Thursday announced it would acquire Swiss biotech Actelion for $30 billion in cash, opening up its wallet to secure Actelion's leading portfolio of treatments for pulmonary arterial hypertension (PAH).
